The Michael J. Fox Foundation has evolved its Parkinson’s Progression Markers Initiative into the Parkinson’s Precision Medicine Initiative, focusing on tailored treatments based on individual biological differences in patients. With over 4,200 clinical participants and more than 47,000 online contributors, this initiative aims to innovate clinical trial designs and ensure treatments align with specific patient profiles, all while advancing research on Parkinson’s disease. The Michael J. Fox Foundation has evolved its Parkinson’s Progression Markers Initiative into the Parkinson’s Precision Medicine Initiative, focusing on tailored treatments based on individual biological differences in patients. With over 4,200 clinical participants and more than 47,000 online contributors, this initiative aims to innovate clinical trial designs and ensure treatments align with specific patient profiles, all while advancing research on Parkinson’s disease.
Trending
- Amazon updates AI usage rules for engineers in new memo
- Upset Palmer Luckey is not leaving California over ‘Billionaire tax’
- Netanyahu seeks ‘right-wing, national, strong govt’ in tight Israel election race
- Oil price today: Brent crude holds firm at $115 per barrel, WTI trades at $100
- NEET-PG counselling: Candidates struggle to join online as colleges remain unreachable
- Karnataka voter roll drops by nearly 1 crore, Gen Z makes up 20% of electorate
- Abhishek Sharma scripts history, breaks Rohit Sharma’s all-time world record
- ‘Ball was still seaming’: Iyer ‘mind-boggled’ by Abhishek, Sooryavanshi’s blitz